↓ Skip to main content

Dove Medical Press

Article Metrics

Imiglucerase in the treatment of Gaucher disease: a history and perspective

Overview of attention for article published in Drug Design, Development and Therapy, April 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

policy
1 policy source
twitter
2 tweeters
facebook
2 Facebook pages
wikipedia
6 Wikipedia pages

Citations

dimensions_citation
49 Dimensions

Readers on

mendeley
114 Mendeley
citeulike
1 CiteULike
Title
Imiglucerase in the treatment of Gaucher disease: a history and perspective
Published in
Drug Design, Development and Therapy, April 2012
DOI 10.2147/dddt.s14395
Pubmed ID
Authors

Timothy Cox

Abstract

The scientific and therapeutic development of imiglucerase (Cerezyme(®)) by the Genzyme Corporation is a paradigm case for a critical examination of current trends in biotechnology. In this article the authors argue that contemporary interest in treatments for rare diseases by major pharmaceutical companies stems in large part from an exception among rarities: the astonishing commercial success of Cerezyme. The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Colombia 1 <1%
Germany 1 <1%
Austria 1 <1%
Unknown 110 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 19%
Student > Bachelor 22 19%
Researcher 22 19%
Student > Ph. D. Student 12 11%
Student > Postgraduate 8 7%
Other 16 14%
Unknown 12 11%
Readers by discipline Count As %
Medicine and Dentistry 30 26%
Agricultural and Biological Sciences 19 17%
Biochemistry, Genetics and Molecular Biology 16 14%
Chemistry 14 12%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 15 13%
Unknown 14 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 April 2020.
All research outputs
#2,999,481
of 17,457,801 outputs
Outputs from Drug Design, Development and Therapy
#146
of 1,724 outputs
Outputs of similar age
#22,190
of 134,155 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 10 outputs
Altmetric has tracked 17,457,801 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,724 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 134,155 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.